ABSTRACT
Pulmonary arterial hypertension (PAH) is associated with impaired release of nitric oxide (1) due, at least in part, to reduced expression of nitric oxide synthase in the vascular endothelium of pulmonary arteries (2). Although inhaled nitric oxide is used for testing acute vasoreactivity (3), its chronic administration is cumbersome and requires a complex delivery system (4).
